Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mirko Scarsi

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Clinical and Experimental Rheumatology|April 14, 2018
Circulating follicular helper T cells (CD4+CXCR5+ICOS+) decrease in patients with rheumatoid arthritis treated with abataceptSilvia Piantoni, Francesca Regola, Mirko Scarsi, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|February 9, 2010
The number of circulating recent thymic emigrants is severely reduced 1 year after a single dose of alemtuzumab in renal transplant recipientsMirko Scarsi, Nicola Bossini, Fabio Malacarne, et al.
The Journal of Rheumatology|May 19, 2009
Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literatureStefania Zingarelli, Micol Frassi, Chiara Bazzani, et al.
Clinical Rheumatology|April 15, 2014
Flow cytometry test to screen for HLA-B*58:01-associated allopurinol hypersensitivityMirko Scarsi, Carla Bosio, Silvia Coccoli, et al.
Rheumatology (Oxford, England)|May 31, 2020
Why not to use colchicine in COVID-19? An oldanti-inflammatory drug for a novel auto-inflammatory diseaseSilvia Piantoni, Andrea Patroni, Paola Toniati, et al.
Journal of Translational Medicine|January 17, 2015
Reduced T-cell repertoire restrictions in abatacept-treated rheumatoid arthritis patientsLuisa Imberti, Mirko Scarsi, Cinzia Zanotti, et al.
The Journal of Rheumatology|October 10, 2008
Upregulation of myxovirus-resistance protein A: a possible marker of type I interferon induction in systemic sclerosisPaolo Airò, Claudia Ghidini, Cinzia Zanotti, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 26, 2009
The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactionsPaolo Airo, Mirko Scarsi, Alberto Malagoli, et al.
Annals of the Rheumatic Diseases|August 29, 2020
Anti-inflammatory action of colchicine in hospitalised patients with COVID-19. Response to: 'Colchicine treatment in community healthcare setting to prevent severe COVID-19' by Della-Torre <i>et al</i>Silvia Piantoni, Enrico Colombo, Roberto Furloni, et al.
The Journal of Rheumatology|March 4, 2014
Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritisMirko Scarsi, Lucia Paolini, Doris Ricotta, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Clinical and Experimental Rheumatology|April 14, 2018
Circulating follicular helper T cells (CD4+CXCR5+ICOS+) decrease in patients with rheumatoid arthritis treated with abataceptSilvia Piantoni, Francesca Regola, Mirko Scarsi, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|February 9, 2010
The number of circulating recent thymic emigrants is severely reduced 1 year after a single dose of alemtuzumab in renal transplant recipientsMirko Scarsi, Nicola Bossini, Fabio Malacarne, et al.
The Journal of Rheumatology|May 19, 2009
Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literatureStefania Zingarelli, Micol Frassi, Chiara Bazzani, et al.
Clinical Rheumatology|April 15, 2014
Flow cytometry test to screen for HLA-B*58:01-associated allopurinol hypersensitivityMirko Scarsi, Carla Bosio, Silvia Coccoli, et al.
Rheumatology (Oxford, England)|May 31, 2020
Why not to use colchicine in COVID-19? An oldanti-inflammatory drug for a novel auto-inflammatory diseaseSilvia Piantoni, Andrea Patroni, Paola Toniati, et al.
Journal of Translational Medicine|January 17, 2015
Reduced T-cell repertoire restrictions in abatacept-treated rheumatoid arthritis patientsLuisa Imberti, Mirko Scarsi, Cinzia Zanotti, et al.
The Journal of Rheumatology|October 10, 2008
Upregulation of myxovirus-resistance protein A: a possible marker of type I interferon induction in systemic sclerosisPaolo Airò, Claudia Ghidini, Cinzia Zanotti, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 26, 2009
The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactionsPaolo Airo, Mirko Scarsi, Alberto Malagoli, et al.
Annals of the Rheumatic Diseases|August 29, 2020
Anti-inflammatory action of colchicine in hospitalised patients with COVID-19. Response to: 'Colchicine treatment in community healthcare setting to prevent severe COVID-19' by Della-Torre <i>et al</i>Silvia Piantoni, Enrico Colombo, Roberto Furloni, et al.
The Journal of Rheumatology|March 4, 2014
Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritisMirko Scarsi, Lucia Paolini, Doris Ricotta, et al.
Pageof 4